Search

Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

New GFI1B variants in bleeding and platelet disorders

Platelets restrict blood loss upon vessel damage by formation of a clot (thrombus). Recently, we reported a family with a bleeding and platelet disorder (BPD), which was caused by a defect in the gene GFI1B1.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more

The European Union must deliver funding for research of blood disorders

At the 20th Annual Congress of EHA, the results of two major projects are presented. The first is a study into the Cost of Blood Disorders in the EU Member States and Norway, Iceland, and Switzerland.

Read more

Training vital for new era of patient-centric healthcare

Christine Chomienne, president of the European Hematology Association (EHA), was speaking at the third annual conference of the European Alliance for Personalised Medicine (EAPM) – a Brussels-based organization that brings together stakeholders from academia, through research,…

Read more

Jesus San Miguel presents the Ham-Wasserman Lecture at the 2014 ASH Annual Meeting

Professor San Miguel is a member of the Advisory board of the International Myeloma Foundation and the Multiple Myeloma Research Foundation.

Read more

Announcement: The award winners of the prestigious EHA-ASH Translational Research in Hematology Training Award are selected

The winners of the TRTH 2015 Awards are:

 

Name

Nationality

Name

Nationality

Ileana Antony-Debre

French

Jean-Baptiste Micol

French

Pavan Bachireddy

American

Christopher Ott

American

Lucile Couronné

French

Carsten Riether

German

Moniek de Witte

Dutch

Anindita Roy

British

Ammon Fager

American

Melody Smith

American

Gillian Horne

British

Zuzana Tothova

Slovakian

Moonjung Jung

South Korea

Marcin Wlodarski

Polish

Jonas Samuel Jutzi

Swiss - German

Yuh-Ying Yeh

Taiwanese

Milka Koupenova-Zamor

American - Bulgarian

Sasan Zandi

Iranian

Marwan Kwok

British

Patricia Maiso

Spain

Are you interested in joining the…

Read more